UF Department of Pediatrics Celebrates Over $3.7 Million for Research
Last month, Children’s Miracle Network Hospitals at UF Health Shands Children’s Hospital celebrated over $3.7 million raised for University of Florida Department of Pediatrics in 2017. Each year, funds from Children’s Miracle Network Hospitals support innovative research within pediatrics. For children with incurable ailments, this research provides hope that the future will be brighter than the present and that complex medical issues of today will become part of our history tomorrow.
Children’s Miracle Network Hospitals research funding provides seed grants for researchers to demonstrate their hypothesis before obtaining nationally funded research grants. Without these vital grants from Children’s Miracle Network Hospitals, many researchers’ work would go untested.
Over 40 researchers at the University of Florida Department of Pediatrics were recognized as grant recipients at the celebration on October 25, 2017.
Several of these recipients were speakers during the program, and shared the impact that Children’s Miracle Network Hospitals has on their work. Speakers included:
Lindsay Thompson, MD, MS- Associate Professor of Pediatrics, General Pediatrics
Emily Sullivan, MS, CHES- Director, Streetlight
Christopher Jolley, MD- Professor and Chief, Pediatrics Gastroenterology
Roland Herzog, PhD- Professor of Pediatrics, Molecular Genetics and Microbiology
“It is an incredible opportunity to have CMN funding to support our ideas, hopes and aspirations,” Dr. Lindsay Thompson said. “This puts UF on the map as a leading department of pediatrics and helps children well into the next generation,” she said. Dr. Thompson is a pediatrician and health services researcher, helping to bridge clinical and research areas at the University of Florida that impact child health.
Children’s Miracle Network Hospitals supports the mission to fund transformational research at UF Health Shands Children’s Hospital. Research projects that have been funded in the past include new treatments for high risk Acute Lymphoblastic Leukemia, multiple sclerosis gene therapy and stem cell therapy.